volume 2, issue 8, PS390 2007
DOI: 10.1097/01.jto.0000283252.39111.1a
View full text
|
|
Share

Abstract: Background:The rationale for this trial was based on the results of a meta analysis on PCI in SCLC complete responders, which showed a significant trend towards a reduction of the brain metastasis (BM) rate among patients who received higher PCI doses. This suggested that it was important to determine if higher dose PCI could further decrease the risk of brain metastases. This is the first trial evaluating the optimal dose for PCI not only in terms of efficacy but also quality of life. Methods: From September …

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
2
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals